



David Collier, MD, CMEA Capital



He currently serves on the Board of Directors of five CMEA portfolio companies: Arcadia Biosciences, Ardelyx, Auspex Pharmaceuticals, Sorbent Therapeutics, and VeraLight, and is Chairman of the Board of Arcion Therapeutics. He also serves as a Board Observer at Bayhill Therapeutics.

Additionally, David was responsible for CMEA's investments in Altus Pharmaceuticals (NASDAQ: ALTU), Biomimetic Pharmaceuticals (NASDAQ: BMTI) and EPIX Pharmaceuticals (NASDAQ: EPIX).

Before joining CMEA, David was a Managing Director at Burrill & Co., a private merchant bank focused exclusively on life science companies, where he played a leading role in the management of the company's life science venture capital funds. Before joining Burrill, David served as a consultant at Arthur D. Little and Magainin Pharmaceuticals.

Earlier in his career, David was Assistant Vice President at First Options of Chicago where he directed a group of traders and managed a large portfolio of futures and options. David has an M.D. from the University of Pennsylvania School of Medicine, an M.B.A. from the Wharton School, and a B.A. in Physics from Wesleyan University.